



07-17-08

CASE OP/4-32328A

TFW
\$

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 971832718 US
Express Mail Label Number7/16/2008
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

BRAZZELL ET AL.

APPLICATION NO: 10/502,180

FILED: JULY 21, 2004

FOR: PHARMACEUTICAL USE OF COX-2-INHIBITORS IN
ANGIOGENESIS-MEDIATED OCULAR DISORDERSCommissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450PETITION FOR EXTENSION OF TIME

Sir:

The Office Action of March 17, 2008 has a shortened statutory time set to expire on April 17, 2008. A three-month extension is hereby requested pursuant to 37 CFR §1.136(a).

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1050 for payment of the extension fee. An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080

Date: July 16, 2008

Jennifer C. Chapman
Attorney for Applicants
Reg. No. 47,487
Phone No. (862) 778-1202

07/17/2008 CCHAU1 00000056 190134 10502180

01 FC:1253 1050.00 DA



CASE OP/4-32328A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 971832718 US
Express Mail Label Number

7/16/2008
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

BRAZZELL ET AL.

APPLICATION NO: 10/502,180

FILED: JULY 21, 2004

FOR: PHARMACEUTICAL USE OF COX-2-INHIBITORS IN
ANGIOGENESIS-MEDIATED OCULAR DISORDERS

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

PETITION FOR EXTENSION OF TIME

Sir:


The Office Action of March 17, 2008 has a shortened statutory time set to expire on April 17, 2008. A three-month extension is hereby requested pursuant to 37 CFR §1.136(a).

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1050 for payment of the extension fee. An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080

Date: July 16, 2008


Jennifer C. Chapman
Attorney for Applicants
Reg. No. 47,487
Phone No. (862) 778-1202